- Conditions
- Primary Open Angle Glaucoma
- Interventions
- AMDX-2011P
- Drug
- Lead sponsor
- Amydis Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Glendale, California • Newport Beach, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–392
of 392
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- T-2345, Xalatan
- Drug
- Lead sponsor
- Nephron Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years to 89 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Not listed
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 39
- States / cities
- Culver City, California • La Jolla, California • Los Angeles, California + 35 more
- Conditions
- Ocular Hypertension, Open Angle-glaucoma
- Interventions
- ONO-9054, Latanoprost
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Mission Hills, California • Newport Beach, California + 9 more
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- LL-BMT1
- Drug
- Lead sponsor
- MediPrint Ophthalmics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- AL-37807 ophthalmic suspension, 0.1%, Timolol gel forming solution, 0.5%, AL-37807 ophthalmic solution vehicle, Latanoprost ophthalmic solution
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Primary Open-angle Glaucoma (POAG), Ocular Hypertension
- Interventions
- SHP639 (n=60), Placebo Comparator (n=24)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts